APAC Anthrax Treatment Market - Industry Trends and Forecast to 2029
- Published Date: 2022-12-22
- Report ID: 143107
- Pages: 225
-
Format:
Short Description
Asia-Pacific Anthrax Treatment Market, By Type (Cutaneous Anthrax, Pulmonary Anthrax and Intestinal Anthrax), Route of Administration (Oral, Parenteral and Others), End User (Government Organization, Hospitals, Academic and Research Institutes, and Others),Country(Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam and Rest of Asia-Pacific) Industry Trends and Forecast to 2029.
Market Definition:
Anthrax is caused by a bacterium called Bacillus anthracis (B. anthracis). It is primarily a disease of livestock that become infected by ingesting spores found in soil. Humans usually become infected with anthrax by handling products of infected animals such as leather or wool or by inhaling anthrax spores from infected animal products. They can also become infected by eating undercooked meat from infected animals. Anthrax is not known to be spread person-to-person.
Three clinical forms of anthrax infection exist. Cutaneous anthrax is the most common, constituting over 95% of reported cases. An estimated 2000 cases of cutaneous anthrax occur worldwide annually and result from the entry of spores through skin abrasions.
The differential diagnosis of anthrax includes depending on the clinical features, relevant specimens include PCR, gram stain, and cultures, from blood, pleural fluid, site of ulceration, cerebrospinal fluid, and stool. A number of available techniques are available. Most assays are based on detecting the entire organism, organism antigens, or organism nucleic acid through one of the following techniques: culture-based conventional methods; immunological detection; nucleic-acid-based assays; ligand-based detection; and biosensors.
Market Segmentation:
Asia-pacific anthrax treatment market is categorized based on type, route of administration and end user.
On the basis of type, the asia-pacific anthrax treatment market is segmented into cutaneous anthrax, pulmonary anthrax and intestinal anthrax
On the basis of route of administration, asia-pacific anthrax treatment market is segmented into oral, parenteral and others
On the basis of end user, asia-pacific anthrax treatment market is segmented into government organization, hospitals, academic and research institutes, and others
Market Players
The key market players for asia-pacific anthrax treatment market are listed below:
Alembic Pharmaceuticals
Sun Pharmaceutical Industries Ltd.
Zydus Group
Bayer AG
Pfizer Inc.
EMERGENT
Sanofi
Lupin
Takeda Pharmaceutical Company Limited
Teva Pharmaceutical Industries Ltd.
ARISTO Pharmaceuticals Private Limited
INDOCO REMEDIES LTD.
GC Biopharma, corp.
TABLE OF CONTENTS
1 INTRODUCTION 74
1.1 OBJECTIVES OF THE STUDY 74
1.2 MARKET DEFINITION 74
1.3 OVERVIEW OF THE ASIA PACIFIC ANTHRAX TREATMENT MARKET 74
1.4 LIMITATIONS 76
1.5 MARKETS COVERED 76
2 MARKET SEGMENTATION 79
2.1 MARKETS COVERED 79
2.2 GEOGRAPHICAL SCOPE 80
2.3 YEARS CONSIDERED FOR THE STUDY 81
2.4 CURRENCY AND PRICING 81
2.5 DBMR TRIPOD DATA VALIDATION MODEL 82
2.6 MULTIVARIATE MODELLING 85
2.7 PRODUCT SEGMENT LIFELINE CURVE 85
2.8 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS 86
2.9 DBMR MARKET POSITION GRID 87
2.10 MARKET APPLICATION COVERAGE GRID 88
2.11 VENDOR SHARE ANALYSIS 89
2.12 SECONDARY SOURCES 90
2.13 ASSUMPTIONS 90
3 EXECUTIVE SUMMARY 91
4 PREMIUM INSIGHTS 95
4.1 PESTEL ANALYSIS 96
4.2 PORTERS FIVE FORCES 97
4.3 DEMOGRAPHIC TRENDS- 98
4.4 EPIDEMIOLOGY AND DEMOGRAPHICS- 100
4.4.1 INCIDENCE 100
4.4.2 DEVELOPED COUNTRIES- 100
4.4.3 DEVELOPING COUNTRIES- 100
4.5 PATIENT ENROLMENT STRATEGIES- 102
4.6 PATIENT FLOW DIAGRAM FOR ANTHRAX INFECTION- 106
4.7 CURRENT STATE OF ANTHRAX VACCINES 108
4.8 ASIA PACIFIC ANTIBIOTIC CONSUMPTION RATES INCREASED BY 46 PERCENT IN THE LAST TWO DECADES, ACCORDING TO THE FIRST STUDY TO PROVIDE LONGITUDINAL ESTIMATES FOR HUMAN ANTIBIOTIC CONSUMPTION COVERING 204 COUNTRIES FROM 2000 TO 2018. 112
4.9 ASIA PACIFIC ANTIBIOTIC CONSUMPTION AND PROJECTED CONSUMPTION- 113
5 THE M&A IN THE ANTHRAX MARKET INDICATES AN UPCOMING LONG RUN IN VACCINE DEVELOPMENT AROUND THE GLOBE. CURRENT AND SOME OF LAST YEARS ACQUISITION BETWEEN LEADERS AND SMALL SIZE PHARMACEUTICAL SHOWS THE CONTINUOUS DEVELOPMENT IN THE COMPANYS PIPELINE FOR ANTHRAX TREATMENT. 117
6 ASIA PACIFIC ANTHRAX TREATMENT MARKET: REGULATIONS 119
7 MARKET OVERVIEW 123
7.1 DRIVERS 125
7.1.1 INCREASING INCIDENCE OF ANTHRAX INFECTION 125
7.1.2 INCREASE IN RESEARCH FUNDING AND THE DEVELOPMENT OF NOVEL THERAPIES FOR THE TREATMENT OF ANTHRAX 125
7.1.3 TECHNOLOGICAL ADVANCEMENTS IN TREATMENT PROCEDURE 126
7.1.4 STRATEGIC INITIATIVES ADOPTED BY MARKET PLAYERS 126
7.2 RESTRAINTS 127
7.2.1 HIGH COST ASSOCIATED WITH ANTHRAX DIAGNOSTIC TREATMENT 127
7.2.2 FALSE DATA INTERPRETATION 128
7.3 OPPORTUNITIES 128
7.3.1 RISING PRODUCT LAUNCHES 128
7.3.2 RISING GOVERNMENT INITIATIVES 129
7.3.3 IMPROVING A BETTER HEALTHCARE SYSTEM 129
7.4 CHALLENGES 130
7.4.1 LACK OF AWARENESS AMONG PEOPLE ABOUT ANTHRAX INFECTION 130
7.4.2 LACK OF SKILLED PROFESSIONALS 130
8 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY TYPE 132
8.1 OVERVIEW 133
8.2 CUTANEOUS ANTHRAX 136
8.2.1 ANTIBIOTICS 137
8.2.1.1 BY DRUGS 137
8.2.1.1.1 CIPROFLOXACIN 138
8.2.1.1.2 LEVOFLOXACIN 138
8.2.1.1.3 DOXYCYCLINE 138
8.2.1.1.4 AMPICILLIN 138
8.2.1.1.5 OTHERS 138
8.2.1.2 BY PRODUCT TYPES 138
8.2.1.2.1 GENERICS 138
8.2.1.2.2 BRANDED 138
8.2.1.2.2.1 CIPRO 139
8.2.1.2.2.2 LEVO 139
8.2.1.2.2.3 DOXY 139
8.2.1.2.2.4 AMPICI 139
8.2.1.2.2.5 OTHERS 139
8.2.2 ANTITOXINS 140
8.2.2.1 RAXIBACUMAB 140
8.2.2.2 OBILTOXAXIMAB (ANTHIM) 140
8.2.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 140
8.2.2.4 OTHERS 140
8.2.3 VACCINES 141
8.2.3.1 RAXIBACUMAB 141
8.2.4 SURGERY 141
8.3 PULMONARY ANTHRAX 141
8.3.1 ANTIBIOTICS 142
8.3.1.1 BY DRUGS 143
8.3.1.1.1 CIPROFLOXACIN 143
8.3.1.1.2 LEVOFLOXACIN 143
8.3.1.1.3 DOXYCYCLINE 143
8.3.1.1.4 AMPICILLIN 143
8.3.1.1.5 OTHERS 143
8.3.1.2 BY PRODUCT TYPES 144
8.3.1.2.1 GENERICS 144
8.3.1.2.2 BRANDED 144
8.3.1.2.2.1 CIPRO 144
8.3.1.2.2.2 LEVO 145
8.3.1.2.2.3 DOXY 145
8.3.1.2.2.4 AMPICI 145
8.3.1.2.2.5 OTHERS 145
8.3.2 ANTITOXINS 145
8.3.2.1 RAXIBACUMAB 145
8.3.2.2 OBILTOXAXIMAB (ANTHIM) 145
8.3.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 145
8.3.2.4 OTHERS 146
8.3.3 VACCINES 146
8.3.3.1 RAXIBACUMAB 146
8.3.3.2 SURGERY 146
8.4 INTESTINAL ANTHRAX 146
8.4.1 ANTIBIOTICS 148
8.4.1.1 BY DRUGS 148
8.4.1.1.1 CIPROFLOXACIN 148
8.4.1.1.2 LEVOFLOXACIN 148
8.4.1.1.3 DOXYCYCLINE 148
8.4.1.1.4 AMPICILLIN 149
8.4.1.1.5 OTHERS 149
8.4.1.2 BY PRODUCT TYPES 149
8.4.1.2.1 GENERICS 149
8.4.1.2.2 BRANDED 149
8.4.1.2.2.1 CIPRO 150
8.4.1.2.2.2 LEVO 150
8.4.1.2.2.3 DOXY 150
8.4.1.2.2.4 AMPICI 150
8.4.1.2.2.5 OTHERS 150
8.4.2 ANTITOXINS 151
8.4.2.1 RAXIBACUMAB 151
8.4.2.2 OBILTOXAXIMAB (ANTHIM) 151
8.4.2.3 ANTHRACIL (ANTHRAX IMMUNE GLOBULIN INTRAVENOUS) 151
8.4.2.4 OTHERS 151
8.4.3 VACCINES 152
8.4.3.1 RAXIBACUMAB 152
8.4.3.2 SURGERY 152
9 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY ROUTE OF ADMINISTRATION 153
9.1 OVERVIEW 154
9.2 PARENTERAL 157
9.3 ORAL 157
9.4 OTHERS 158
10 ASIA PACIFIC ANTHRAX TREATMENT MARKET, BY END USER 159
10.1 OVERVIEW 160
10.2 GOVERNMENT ORGANIZATION 163
10.3 HOSPITALS 163
10.4 ACADEMIC AND RESEARCH 164
10.5 OTHERS 166
11 ASIA PACIFIC VIRTUAL REALITY MARKET, BY GEOGRAPHY 167
11.1 ASIA-PACIFIC 168
11.1.1 CHINA 184
11.1.2 JAPAN 195
11.1.3 SOUTH KOREA 206
11.1.4 INDIA 217
11.1.5 AUSTRALIA 228
11.1.6 SINGAPORE 239
11.1.7 THAILAND 250
11.1.8 MALAYSIA 261
11.1.9 INDONESIA 272
11.1.10 PHILIPPINES 282
11.1.11 REST OF ASIA-PACIFIC 293
12 ASIA PACIFIC ANTHRAX TREATMENT MARKET, COMPANY LANDSCAPE 294
12.1 COMPANY SHARE ANALYSIS: ASIA PACIFIC 294
13 SWOT ANALYSIS 295
14 COMPANY PROFILE 296
14.1 BAYER AG 296
14.1.1 COMPANY SNAPSHOT 296
14.1.2 REVENUE ANALYSIS 296
14.1.3 COMPANY SHARE ANALYSIS 297
14.1.4 PRODUCT PORTFOLIO 297
14.1.5 RECENT DEVELOPMENTS 297
14.2 PFIZER INC. 298
14.2.1 COMPANY SNAPSHOT 298
14.2.2 REVENUE ANALYSIS 298
14.2.3 COMPANY SHARE ANALYSIS 299
14.2.4 PRODUCT PORTFOLIO 299
14.2.5 RECENT DEVELOPMENTS 299
14.3 TEVA PHARMACEUTICAL INDUSTRIES LTD 300
14.3.1 COMPANY SNAPSHOT 300
14.3.2 REVENUE ANALYSIS 300
14.3.3 COMPANY SHARE ANALYSIS 301
14.3.4 PRODUCT PORTFOLIO 301
14.3.5 RECENT DEVELOPMENT 301
14.4 SANOFI 302
14.4.1 COMPANY SNAPSHOT 302
14.4.2 REVENUE ANALYSIS 302
14.4.3 COMPANY SHARE ANALYSIS 303
14.4.4 PRODUCT PORTFOLIO 303
14.4.5 RECENT DEVELOPMENTS 303
14.5 TAKEDA PHARMACEUTICAL COMPANY LIMITED. 304
14.5.1 COMPANY SNAPSHOT 304
14.5.2 REVENUE ANALYSIS 304
14.5.3 PRODUCT PORTFOLIO 305
14.5.4 RECENT DEVELOPMENT 305
14.6 ALEMBIC PHARMACEUTICALS LIMITED 306
14.6.1 COMPANY SNAPSHOT 306
14.6.2 PRODUCT PORTFOLIO 306
14.6.3 RECENT DEVELOPMENTS 306
14.7 ALTIMMUNE 307
14.7.1 COMPANY SNAPSHOT 307
14.7.2 REVENUE ANALYSIS 307
14.7.3 PRODUCT PORTFOLIO 308
14.7.4 RECENT DEVELOPMENTS 308
14.8 ARISTO PHARMACEUTICALS PRIVATE LIMITED 309
14.8.1 COMPANY SNAPSHOT 309
14.8.2 PRODUCT PORTFOLIO 309
14.8.3 RECENT DEVELOPMENTS 309
14.9 BLUEWILLOW BIOLOGICS. 310
14.9.1 COMPANY SNAPSHOT 310
14.9.2 PRODUCT PORTFOLIO 310
14.9.3 RECENT DEVELOPMENTS 310
14.10 DEINOVE 311
14.10.1 COMPANY SNAPSHOT 311
14.10.2 REVENUE ANALYSIS 311
14.10.3 PRODUCT PORTFOLIO 312
14.10.4 RECENT DEVELOPMENTS 312
14.11 EMERGENT 313
14.11.1 COMPANY SNAPSHOT 313
14.11.2 REVENUE ANALYSIS 313
14.11.3 PRODUCT PORTFOLIO 314
14.11.4 RECENT DEVELOPMENTS 314
14.12 ELUSYS THERAPEUTICS INC. 315
14.12.1 COMPANY SNAPSHOT 315
14.12.2 PRODUCT PORTFOLIO 315
14.12.3 RECENT DEVELOPMENTS 315
14.13 GC BIOPHARMA CORP. 316
14.13.1 COMPANY SNAPSHOT 316
14.13.2 REVENUE ANALYSIS 316
14.13.3 PRODUCT PORTFOLIO 317
14.13.4 RECENT DEVELOPMENTS 317
14.14 INDOCO REMEDIES LTD. 318
14.14.1 COMPANY SNAPSHOT 318
14.14.2 REVENUE ANALYSIS 318
14.14.3 PRODUCT PORTFOLIO 319
14.14.4 RECENT DEVELOPMENTS 319
14.15 INTEGRATED BIOTHERAPEUTICS, INC. 320
14.15.1 COMPANY SNAPSHOT 320
14.15.2 PRODUCT PORTFOLIO 320
14.15.3 RECENT DEVELOPMENTS 320
14.16 LUPIN. 321
14.16.1 COMPANY SNAPSHOT 321
14.16.2 REVENUE ANALYSIS 321
14.16.3 PRODUCT PORTFOLIO 322
14.16.4 RECENT DEVELOPMENTS 322
14.17 PARATEK PHARMACEUTICALS, INC. 323
14.17.1 COMPANY SNAPSHOT 323
14.17.2 REVENUE ANALYSIS 323
14.17.3 PRODUCT PORTFOLIO 324
14.17.4 RECENT DEVELOPMENTS 324
14.18 PORTON BIOPHARMA 325
14.18.1 COMPANY SNAPSHOT 325
14.18.2 PRODUCT PORTFOLIO 325
14.18.3 RECENT DEVELOPMENTS 325
14.19 SOLIGENIX 326
14.19.1 COMPANY SNAPSHOT 326
14.19.2 REVENUE ANALYSIS 326
14.19.3 PRODUCT PORTFOLIO 327
14.19.4 RECENT DEVELOPMENTS 327
14.20 SUN PHARMACEUTICAL INDUSTRIES LTD. 328
14.20.1 COMPANY SNAPSHOT 328
14.20.2 REVENUE ANALYSIS 328
Call Us
( India toll free )
+91 835 605 0278
( US toll free )
+1 800 601 6071
Drop us an email at
sales@prudentmarkets.com
Get your pre and post sales queries resolved by our Subject matter experts.
We will assist you to customize the report to fit your research needs.
Our prime focus is to provide qualitative and accurate data.
Feel free to order a sample report before purchase.
Your personal and confidential information is safe and secured.
